Historical Valuation
Elevance Health Inc (ELV) is now in the Undervalued zone, suggesting that its current forward PE ratio of 13.23 is considered Undervalued compared with the five-year average of 13.75. The fair price of Elevance Health Inc (ELV) is between 413.48 to 495.50 according to relative valuation methord. Compared to the current price of 374.77 USD , Elevance Health Inc is Undervalued By 9.36%.
Relative Value
Fair Zone
413.48-495.50
Current Price：374.77
9.36%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Elevance Health Inc (ELV) has a current Price-to-Book (P/B) ratio of 1.79. Compared to its 3-year average P/B ratio of 2.54 , the current P/B ratio is approximately -29.41% higher. Relative to its 5-year average P/B ratio of 2.71, the current P/B ratio is about -33.88% higher. Elevance Health Inc (ELV) has a Forward Free Cash Flow (FCF) yield of approximately 4.78%. Compared to its 3-year average FCF yield of 5.35%, the current FCF yield is approximately -10.62% lower. Relative to its 5-year average FCF yield of 6.51% , the current FCF yield is about -26.55% lower.
P/B
Median3y
2.54
Median5y
2.71
FCF Yield
Median3y
5.35
Median5y
6.51
Competitors Valuation Multiple
AI Analysis for ELV
The average P/S ratio for ELV competitors is 0.34, providing a benchmark for relative valuation. Elevance Health Inc Corp (ELV.N) exhibits a P/S ratio of 0.39, which is 14.91% above the industry average. Given its robust revenue growth of 12.33%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ELV
1Y
3Y
5Y
Market capitalization of ELV increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ELV in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ELV currently overvalued or undervalued?
Elevance Health Inc (ELV) is now in the Undervalued zone, suggesting that its current forward PE ratio of 13.23 is considered Undervalued compared with the five-year average of 13.75. The fair price of Elevance Health Inc (ELV) is between 413.48 to 495.50 according to relative valuation methord. Compared to the current price of 374.77 USD , Elevance Health Inc is Undervalued By 9.36% .
What is Elevance Health Inc (ELV) fair value?
ELV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Elevance Health Inc (ELV) is between 413.48 to 495.50 according to relative valuation methord.
How does ELV's valuation metrics compare to the industry average?
The average P/S ratio for ELV's competitors is 0.34, providing a benchmark for relative valuation. Elevance Health Inc Corp (ELV) exhibits a P/S ratio of 0.39, which is 14.91% above the industry average. Given its robust revenue growth of 12.33%, this premium appears unsustainable.
What is the current P/B ratio for Elevance Health Inc (ELV) as of Jan 09 2026?
As of Jan 09 2026, Elevance Health Inc (ELV) has a P/B ratio of 1.79. This indicates that the market values ELV at 1.79 times its book value.
What is the current FCF Yield for Elevance Health Inc (ELV) as of Jan 09 2026?
As of Jan 09 2026, Elevance Health Inc (ELV) has a FCF Yield of 4.78%. This means that for every dollar of Elevance Health Inc’s market capitalization, the company generates 4.78 cents in free cash flow.
What is the current Forward P/E ratio for Elevance Health Inc (ELV) as of Jan 09 2026?
As of Jan 09 2026, Elevance Health Inc (ELV) has a Forward P/E ratio of 13.23. This means the market is willing to pay $13.23 for every dollar of Elevance Health Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Elevance Health Inc (ELV) as of Jan 09 2026?
As of Jan 09 2026, Elevance Health Inc (ELV) has a Forward P/S ratio of 0.39. This means the market is valuing ELV at $0.39 for every dollar of expected revenue over the next 12 months.